Clinical trial · Interventional
Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
A Phase I Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
NCT07063407CI-TRIAL-00092116not yet recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Lung Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HS-20093 in combination with Adebrelimab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HS-20093 and Adebrelimab
- interventionNames
- Drug: HS-20093 in combination with Adebrelimab
Primary outcomes (1)
- measure
- Pogression-free survival (PFS) determined by investigators according to RECIST 1.1
- timeFrame
- up to approximately 24 months
- description
- PFS is defined as the time from date of first dose until the documentation of objective PD or death from any cause in the absence of progression (whichever occurred first), regardless of whether they subsequently received non-study anti-cancer therapy.
Secondary outcomes (8)
- measure
- Incidence of adverse events (AEs)
- timeFrame
- From the first dose through 90 days post end of treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for participation in this study: 1. Men or women aged more than or equal to (≥) 18 years. 2. Pathologically diagnosed as ES-SCLC. 3. Without disease progression after receiving first-line standard induction therapy (Platinum + Etoposide +PD- (L) 1 inhibitor combination therapy). 4. Eastern Cooperative Oncology Group (ECOG) performance status: 0\~1. 5. Estimated life expectancy \>12 weeks. 6. Adequate bone marrow reserve or serious organ dysfunction 7. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit. 8. Females must have evidence of non-childbearing potential. 9. Signed and dated Informed Consent Form. Exclusion Criteria: 1. Uncontrolled pleural effusion or ascites or pericardial effusion. 2. Known and untreated, or active central nervous system metastases. 3. Active autoimmune diseases or active infectious disease 4. Known to have interstitial pneumonia or immune pneumonia 5. History of severe allergic reaction, serious transfusion reactions or Allergy to any component of HS-20093 6. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator. 7. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator. 8. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study. 9. History of neuropathy or mental disorders, including epilepsy and dementia.
References
Publications (0)
Data not yet available
No reference posted for this study.